215 Nordre Fasanvej Frederiksberg, Hovedstaden, 2000 DenmarkBioPhenyx delivers clinically validated functional genomics for precision medicine by generating causal biological evidence where conventional methods often provide only predictions or correlations. BioPhenyx is a Danish functional genomics company developing and applying its proprietary CRISPR-Sure™ and CRISPR-Select™ technologies to generate high-quality causal biological data for drug discovery, target validation, precision medicine, and variant interpretation. The company's platform enables rapid, quantitative and highly reproducible assessment of gene and variant function directly in relevant cellular systems. Unlike conventional approaches that often rely on correlations, statistical associations, clonal cell lines, or AI-based predictions, BioPhenyx provides direct functional evidence by introducing genetic variants alongside internal controls and measuring their biological impact in pooled cell populations. This enables precise characterization of disease-associated variants, gene function, and drug responses in a standardized and scalable format. Core Capabilities Functional Variant Interpretation Assessment of SNVs, indels, and splice-site variants Quantitative classification of variants of uncertain significance (VUS) Generation of evidence supporting pathogenicity or benignity assessments Clinical-grade functional validation workflows Target Validation Functional validation of novel therapeutic targets Loss-of-function and variant-effect studies Assessment of gene dependency and biological relevance Rapid turnaround compared with traditional clonal cell-line approaches Drug Response Profiling Evaluation of variant-specific drug responses Identification of resistance and sensitivity mechanisms Support for companion diagnostic and precision medicine development Patient stratification studies Custom Functional Genomics Studies Disease-specific assay development Oncology-focused functional studies High-throughput CRISPR-Sure™ assays Customized cell-based functional investigations Technology Advantages CRISPR-Sure™ enables: Direct causal biological measurements Internal normalization controls for high accuracy and reproducibility Quantitative and conclusive functional readouts Analysis of clinically relevant variants in virtually any cell type Scalability through automation and robotics Turnaround times typically within 1-2 weeks for many applications Therapeutic Areas BioPhenyx has particular expertise in: Hereditary cancer syndromes Lynch Syndrome Precision oncology Variant interpretation and molecular diagnostics Functional genomics and translational medicine The company has established clinically validated assays for key Lynch Syndrome genes including MLH1, MSH2 and MSH6, supporting applications in VUS classification and precision medicine development.

Ole Maaløes Vej 3 Copenhagen N, Capital Region, 2200 DenmarkBioPhenyx delivers clinically validated functional genomics for precision medicine by generating causal biological evidence where conventional methods often provide only predictions or correlations. BioPhenyx is a Danish functional genomics company developing and applying its proprietary CRISPR-Sure™ and CRISPR-Select™ technologies to generate high-quality causal biological data for drug discovery, target validation, precision medicine, and variant interpretation. The company's platform enables rapid, quantitative and highly reproducible assessment of gene and variant function directly in relevant cellular systems. Unlike conventional approaches that often rely on correlations, statistical associations, clonal cell lines, or AI-based predictions, BioPhenyx provides direct functional evidence by introducing genetic variants alongside internal controls and measuring their biological impact in pooled cell populations. This enables precise characterization of disease-associated variants, gene function, and drug responses in a standardized and scalable format. Core Capabilities Functional Variant Interpretation Assessment of SNVs, indels, and splice-site variants Quantitative classification of variants of uncertain significance (VUS) Generation of evidence supporting pathogenicity or benignity assessments Clinical-grade functional validation workflows Target Validation Functional validation of novel therapeutic targets Loss-of-function and variant-effect studies Assessment of gene dependency and biological relevance Rapid turnaround compared with traditional clonal cell-line approaches Drug Response Profiling Evaluation of variant-specific drug responses Identification of resistance and sensitivity mechanisms Support for companion diagnostic and precision medicine development Patient stratification studies Custom Functional Genomics Studies Disease-specific assay development Oncology-focused functional studies High-throughput CRISPR-Sure™ assays Customized cell-based functional investigations Technology Advantages CRISPR-Sure™ enables: Direct causal biological measurements Internal normalization controls for high accuracy and reproducibility Quantitative and conclusive functional readouts Analysis of clinically relevant variants in virtually any cell type Scalability through automation and robotics Turnaround times typically within 1-2 weeks for many applications Therapeutic Areas BioPhenyx has particular expertise in: Hereditary cancer syndromes Lynch Syndrome Precision oncology Variant interpretation and molecular diagnostics Functional genomics and translational medicine The company has established clinically validated assays for key Lynch Syndrome genes including MLH1, MSH2 and MSH6, supporting applications in VUS classification and precision medicine development.